Technologically superior products often fail because they disrupt clinical workflows. To succeed, companies must integrate workflow considerations from the very beginning of the design process, viewing the product as a complete solution, not just an engineering project.
Startups often rush to publicize their first patient enrollment. A better approach is to treat the entire first-in-human study as a rigorous experiment focused on learning and optimization, delaying major marketing until after the trial is successfully completed.
Strong data from controlled trials will open doors, but it won't guarantee broad adoption. True success comes from a product's predictable, reliable performance in everyday clinical settings, which are far more chaotic than an investigational site.
To get adopted, a technology must speak three languages. It needs to provide excellent clinical outcomes for physicians, operational efficiency for staff, and a positive economic impact for hospital administrators. Excelling in only one area is not enough.
Before starting a trial, define specific safety and efficacy alarms or 'stop rules.' This disciplined approach allows a company to terminate a failing study early, preserving capital and resources, rather than waiting until the end to discover the results are not viable.
Focusing on a single, narrow application limits long-term growth. By designing a scalable platform from the outset, MedTech companies can adapt their core technology to other procedures and markets, ensuring future viability and expansion opportunities.